Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16 JPY | 0.00% | -5.88% | -30.43% |
Apr. 29 | Poland's Tusk calls prosecutor over potential Orlen scandal | RE |
Apr. 22 | OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024 | CI |
Sales 2022 | 1.15B 7.4M | Sales 2023 | 1.13B 7.28M | Capitalization | 9.05B 58.12M |
---|---|---|---|---|---|
Net income 2022 | -2.57B -16.5M | Net income 2023 | -1.12B -7.18M | EV / Sales 2022 | 9.94 x |
Net cash position 2022 | 1.84B 11.79M | Net cash position 2023 | 1.12B 7.17M | EV / Sales 2023 | 7 x |
P/E ratio 2022 |
-5.03
x | P/E ratio 2023 |
-8.1
x | Employees | 60 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.94% |
1 week | -11.11% | ||
Current month | -5.88% | ||
1 month | -20.00% | ||
3 months | -11.11% | ||
6 months | -38.46% | ||
Current year | -30.43% |
Managers | Title | Age | Since |
---|---|---|---|
Junichi Shimada
PSD | President | 62 | 21-11-30 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Hatsuo Kato
CHM | Chairman | 80 | 20-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 16 | 0.00% | 2 861 900 |
24-05-14 | 16 | 0.00% | 3,076,300 |
24-05-13 | 16 | 0.00% | 4,411,600 |
24-05-10 | 16 | -5.88% | 3,840,400 |
24-05-09 | 17 | -5.56% | 4,766,900 |
Delayed Quote Japan Exchange, May 15, 2024 at 02:00 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-30.43% | 22.26M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.44% | 21.25B | |
-5.80% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- 4564 Stock